期刊
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
卷 5, 期 6, 页码 887-897出版社
SAGE PUBLICATIONS INC
DOI: 10.1177/2050640617691690
关键词
Diarrhea-predominant irritable bowel syndrome; disodium cromoglycate; intestinal innate immunity; mast cell; Toll-like receptors
资金
- Fondo Europeo de Desarrollo Regional (FEDER)
- Fondo de Investigacion Sanitaria
- CIBEREHD
- Instituto de Salud Carlos III
- Subdireccion General de Investigacion Sanitaria
- Ministerio de Economia, Industria y Competitividad [CM08/00229, CM05/00055, CP10/00502, PI13/ 00935, PI 15/00301, PI12/00314, EII2011-0035, CD15/00010, PI08/0940, EC07/90148, PI11/00716, PI14/00994]
- Ministerio de Educacion
- Direccion General de Investigacion [SAF 2009-07416]
- Agencia de Gestiod'Ajuts Universitaris i de Recerca, de la Generalitat de Catalunya [SGR 219]
- International Foundation for Functional Gastrointestinal Disorders (IFFGD)
Background and goal: Diarrhoea-predominant irritable bowel syndrome (IBS-D) exhibits intestinal innate immune and mucosal mast cell (MC) activation. MC stabilisers have been shown to improve IBS symptoms but the mechanism is unclear. Our primary aim was to investigate the effect of oral disodium cromoglycate (DSCG) on jejunal MC activation and specific innate immune signalling pathways in IBS-D, and secondarily, its potential clinical benefit. Study: Mucosal MC activation (by ultrastructural changes, tryptase release and gene expression) and innate immune signalling (by protein and gene expression) were quantified in jejunal biopsies from healthy (HS; n=16) and IBS-D subjects after six months of either treatment with DSCG (600mg/day, IBS-D-DSCG group; n=18) or without treatment (IBS-D-NT group; n=25). All IBS-D patients recorded abdominal pain and bowel habits at baseline and in the last 10 days prior to jejunal sampling. Results: IBS-D-NT exhibited significant MC activation and over-expression of immune-related genes as compared to HS, whereas in IBS-D-DSCG MC activity and gene expression were similar to HS. Furthermore, DSCG significantly reduced abdominal pain and improved stool consistency. Conclusion: Oral DSCG modulates mucosal immune activity and improves gut symptoms in IBS-D patients. Future placebo-controlled clinical trials are needed for confirmation of clinical benefit of DSCG for IBS-D.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据